Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Endothelial Progenitor Cell Capture Stent With 1 Months Dual Antiplatelet Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥70 years patients with coronary artery disease (≤stable angina CCS III, Unstable angina IIb~* patients with signed informed consent~* significant coronary artery stenosis (\>50%) considered for coronary stenting~* Reference vessel diameter of 2.5 to 4.0 mm~Exclusion Criteria:~* The patient has a known hypersensitivity or contraindication to any of the following medications: Heparin, Aspirin, Clopidogrel, Everolimus, Contrast media (Patients with documented sensitivity to contrast media which can be effectively premedicated with steroids and diphenhydramine \[e.g. rash\] may be enrolled. Those with true anaphylaxis to prior contrast media, however, should not be enrolled.)~* Systemic (intravenous) Everolimus use within 12 months~* The patients who are receiving anticoagulants or anti-platelet medications besides aspirin \& clopidogrel~* History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia), or refuses blood transfusions~* Baseline hemogram with Hb\<10g/dL or PLT count \<100,000/μL~* Severe Hepatic dysfunction (≥ 3 times normal reference values)~* Significant renal dysfunction (Serum creatinine ≥ 2.0 mg/dl)~* Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months~* Patients with LV systolic dysfunction (LVEF\<40%) or in cardiogenic shock~* Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment)~* Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period~* An elective surgical procedure is planned that would necessitate interruption of DAPT during the first 12 months post enrollment

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Genous stent group (Type: ACTIVE_COMPARATOR): Genous stent (Endothelial progenitor cell capture stent) insertion in elderly patients with stable coronary artery disease
- Xience stent group (Type: ACTIVE_COMPARATOR): Xience Prime V stent (everolimus eluting stent) insertion in elderly patients with stable coronary artery disease
- Atorvastatin 20mg group (Type: ACTIVE_COMPARATOR): None
- Atorvastatin 80mg group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).